Chemical Science

Ligand binding to intrinsically disordered proteins resists description in terms of conventional binding pockets, yet it can be analysed as a dynamic process in which ligands move across transient surface interaction sites. Here we characterise a pathway-based representation in which ligand binding is described as a sequence of transitions between residue-defined microstates, enabling ligand-specific effects to be distinguished from intrinsic properties of the peptide conformational ensemble. Using all-atom molecular dynamics simulations of A{beta}42 and the C-terminal region of -synuclein in complex with chemically diverse small molecules, we construct transition matrices that encode ligand movement across the peptide surface and use Markov state models to identify dominant binding pathways and relative binding propensities. Pairwise enrichment-factor and AUC analyses reveal strong conservation of the highest-ranked pathways across chemically diverse ligands, with enrichment factors of 15-45 for the top-ranked states and AUC values typically [≥]0.75, well above random expectation. These dominant pathways are also preserved across changes in pH and temperature, whereas a urea control, included as a non-specific binder, shows reduced enrichment, indicating that ligands primarily modulate pathway weights rather than define the underlying network topology. Ensemble docking across chemically diverse libraries further supports the presence of recurrent ligand-accessible hotspots within the peptide conformational ensemble. Building on this framework, we apply a prospective screening pipeline to A{beta}42, combining MSM-derived hotspots with sequence-based Ligand-Transformer scoring and Gnina docking across 1.66 million compounds, to nominate 19 candidates for prospective experimental evaluation. Together, these results indicate that disordered protein sequences give rise to conformational ensembles that exhibit characteristic binding pathways for small molecules.

Mycobacterium tuberculosis fatty acid synthase I (Mtb FAS-I) is a multifunctional hexameric complex essential for fatty acid (FA) synthesis. The need of a hexameric structure for activity of the complex in Mtb remains elusive. Here, we model a conformation of the functionally active complex with acyl carrier protein (ACP) at ketoacyl synthase (KS). Our model reveals a crucial cross-dome dependence in the mechanism of FA synthesis at the condensation step. Using molecular dynamics simulation, we identify key ACP and KS residues that mantain persistent interactions. ACPs phosphopantetheine (PPT) arm adopts several conformations while accessing KSs catalytic pocket, including two distinct conformations that correlate with volumes of ACP and KS pockets. A PHE residue, reported as a gatekeeper of the KS pocket in other species, also shows open and closed orientations in our simulation. Our results provide crucial insights that are essential for a mechanistic undersanding of the Mtb FAS-I complex.

The standard set of 20 genetically-encoded amino acids (C20) exhibits a statistically non-random distribution in primarily two structurally-relevant physicochemical properties: hydrophobicity and molecular volume, and to a lesser extent charge. It remains an open question, however, whether evolutionary pressures similarly optimized the same alphabet for the distribution of functionally-relevant properties, such as reactivity. In this study, we used semi-empirical quantum chemistry simulations to calculate the highest occupied molecular orbital and lowest unoccupied molecular orbital (HOMO-LUMO) gaps for 84 xeno amino acids and constructed 10 million random 20-mer amino acid alphabets to determine where C20 fit amongst this background. The HOMO-LUMO gap measurements demonstrated that C20, similar to hydrophobicity and volume, also exhibits a non-random distribution. However, unlike hydrophobicity and volume, this distribution is non-random across an unevenly broad range. The results expand upon previous theory and suggest HOMO-LUMO gap energies as one synthetic biologists may consider when developing novel protein design tools or designing functional xeno amino acid alphabets. HighlightsO_LILifes amino acid alphabet is non-randomly distributed within an expanded computationally-generated chemistry space generated from large-scale quantum chemistry simulations. C_LIO_LIAmino acid alphabet coverage theory applies beyond structurally-relevant physicochemical descriptors to include functionally-relevant properties like reactivity as measured by frontier molecular orbitals C_LIO_LIFindings here provide a theoretical framework to guide the design of novel proteins and development of synthetic amino acid alphabets. C_LI

Cytochrome P450s catalyze a diverse array of reactions including crosslinking of aromatic side chains in the biosynthesis of ribosomally synthesized and post-translationally modified peptides (RiPPs). ApyO is a cytochrome P450 enzyme that forms a C-C bond between two tyrosines in a YLY motif in the substrate ApyA, the precursor peptide of the RiPP aminopyruvatide. We utilized cell-free translation to generate ApyA variants and probe the substrate tolerance of ApyO. Through Alphafold-based modelling and in vitro assays, we show that ApyO accepts the 10 C-terminal residues of ApyA and requires a conserved Arg/Lys in the substrate peptide. Inspired by substrate sequences found in orthologous biosynthetic gene clusters, we substituted one of the tyrosine residues with a tryptophan and observed that ApyO catalyzed the formation of an N-C bond between the indole of Trp and the C{varepsilon}2 of Tyr. ApyO unexpectedly catalyzed formation of a C-O bond between the two tyrosine residues when we substituted the leucine residue in the YLY motif with tyrosine and tryptophan. We also show that a peptide containing a biaryl linkage and the C-terminal aminopyruvate displayed sub-nanomolar inhibitory activity against selected proteases. Overall, this study demonstrates plasticity in the manner of macrocyclization catalyzed by the P450 ApyO and provides a starting point for chemoenzymatic approaches towards producing diverse macrocyclic scaffolds.

We introduce the Serna Bio GenAI platform, a generative chemistry and multiparametric optimization platform for the design of RNA-targeting small molecules. Targeting RNA with small molecules has proven historically challenging but offers notable potential upsides, including access to unique mechanisms of action and the ability to target otherwise untargetable genes. We consider a major challenge here to be designing chemistry specific to RNA-targeting. Molecular design is a valuable application of AI in drug discovery, but many publicly available models use training data focused on protein-targeting - the modality best historically explored in drug discovery. We showcase the difference and value in building a specifically RNA-targeting platform, comparing its performance to state-of-the-art public chemical generators and experimentally validating its chemical designs in comparison to chemistry designed by a human expert.

Protein labelling by covalent attachment of a specific substrate to a self-labelling protein tag has become a regular in the life sciences. Herein, we report the design of a two-component labelling system, comprised of a non-fluorescent difluorinated xanthene, called F2X, and a HaloTag mutant engineered for targeted reactivity towards F2X. Upon primary covalent locking of the ligand at the canonical aspartate residue, two proximal lysine residues located at the protein surface can undergo nucleophilic aromatic substitution with the F2X core, building a fluorescent rhodamine via triple-covalent fusion. We used a generalizable in silico pipeline for heuristic conformational sampling of covalent protein-ligand complexes to find suitable mutation sites, culminating in the curation of 7 double-lysine HaloTag mutants for targeted in vitro testing. Reaction with the best-performing mutant, HTPL161K_Q165K, is characterized by full protein mass spectrometry, fluorescence polarization fluorescence lifetime, and fluorescence anisotropy and rationalized by computational modelling. We showcase the system in single molecule microscopy, where obviation of post-labelling purification is a prime advantage when targeting recombinant proteins that may not be expressed in larger quantities, and employ F2X in living cells with reduced photobleaching. Lastly, a cell-impermeable version was obtained by means of sulfonation, exclusively targeting extracellularly exposed HTPKK fused to the neuromodulatory G protein-coupled receptor metabotropic glutamate receptor 2.

Kinases have proven to be one of the most fertile target classes for new drug approvals. However, classical reversible inhibitors may not be capable of the levels of specificity or target modulation required across a broad spectrum of disease areas. Approaches that chemically modify kinase inhibitors in solvent exposed regions are unveiling a swathe of mechanisms to address kinase function in new ways. For example, by either covalently recruiting nucleophilic residues outside of the ATP-binding pocket to inhibit, or by recruiting secondary effector proteins to degrade. Here, we systematically assessed the impact of minimal electrophilic modifications to ATP-site binding scaffolds, leading us to identify molecules that can control the activity and abundance of the master autophagy regulator, Unc-51-like autophagy activating kinase 1 (ULK1).

Computer-aided drug design for conditional biomolecular interfaces requires evaluation across more than one receptor structure, docking pose, or scalar score. LINE-1 ORF1p is treated here as a state-family interface target whose relevant behavior is distributed across receptor microstates, assembly-compatible contact neighborhoods, ligand conformers, and perturbation snapshots. This article presents Linobectide as a mathematical-chemistry CADD workflow centered on a modified black-hole algorithm (MBHA) for persistence-weighted prioritization of putative ORF1p inhibitor candidates. Each molecule is represented as a dossier containing standardized descriptors, docking annotations, interaction-class persistence vectors, finite-action stability traces, graph-localization summaries, SPECTRAL-SAR applicability-domain records, and rank-shift diagnostics. The revised analysis emphasizes numerical reporting endpoints: fixed run parameters, baseline comparators, ablation metrics, rank stability, regeneration fractions, protected-elite fractions, and reproducibility indices. Docking is used as an annotation layer rather than as a stand-alone proof of inhibition. The framework is therefore reported as a transparent computational prioritization protocol that generates testable hypotheses for future biochemical and cellular validation, not as experimental proof of ORF1p inhibition or therapeutic activity. Author summaryDrug-design workflows can become over-dependent on the best docking pose even when an interface target remains functional through alternative contact corridors. Linobectide addresses this issue by ranking candidates only after docking annotations are aggregated across receptor-state and perturbation conditions. The MBHA search promotes a candidate when interaction persistence, finite-action stability, graph localization, SPECTRAL-SAR coherence, applicability-domain support, and reproducibility checks are concordant. The revision removes unsupported claims of performance advantage and replaces them with benchmarkable endpoints that can be compared with docking-only, consensus-docking, and ablated MBHA baselines. The SI Appendix is retained as a figure atlas for state-family construction, graph-localization diagnostics, docking provenance, consensus geometry, and comparative triage.

Designing peptide sequences that remain stable and selective across heterogeneous environments remains a central challenge in biomolecular modeling. Here we introduce an interpretable, physics-based Hamiltonian for environment-conditioned design of -helical peptide sequences. The model integrates helix propensities, pairwise interactions, electrostatics, anisotropic solvent exposure, and interfacial geometry into a unified energy function. To enable comparison across sequence lengths and environments, all contributions are rescaled and expressed as Z-scores relative to random sequence ensembles, yielding a normalized design landscape with balanced physical terms. This formulation defines a structured optimization problem that can be explored using exact, heuristic, and hybrid quantum- classical approaches without modification of the underlying model. The Hamiltonian recovers polar and apolar limits, discriminates experimentally characterized water-soluble and transmembrane -helical peptide sequences, and captures the preferential stabilization of membrane-active sequences at anionic interfaces over non-functional controls. It further enables multi-objective and selective design, generating candidate sequences with tunable environmental specificity.

Antibiotic resistance in Mycobacterium tuberculosis is a pressing global health challenge demanding new therapeutic strategies. The bacterial respiratory chain comprises promising antibacterial targets, with dual inhibition of the terminal oxidases cytochrome bcc:aa3 and cytochrome bd (cyt bd) showing bactericidal activity. While bcc:aa3 inhibitors such as Q203 have advanced clinically, cyt bd remains underexplored due to difficulties in assigning activity of the purified enzyme and structurally resolving the quinol substrate binding site. Here, we report a rapid in vitro screening platform for cyt bd inhibitors by engineering a minimal respiratory system that couples the activity of cyt bd to that of a type 2 NADH dehydrogenase. This coupled assay enables spectroscopic monitoring of NADH oxidation as a proxy for cyt bd activity, allowing rapid screening of over 10,000 compounds. Screening identified WSL017, a fragment with low micromolar potency against both M. tuberculosis and E. coli cyt bd. Kinetic and structural analyses revealed competitive inhibition at the quinol-binding site, providing the first structural insights into cyt bd inhibition by a non-quinone scaffold. WSL017 displayed growth inhibition of M. tuberculosis H37ra, corroborating oxidase inhibition as a promising therapeutic strategy. This work establishes a pipeline for cyt bd inhibitor discovery and highlights new opportunities for structure-guided drug development against cytochrome bd oxidases.

Malaria remains one of the major threats to human health. Breakthrough drugs with high potency and low resistance risk are needed to combat the ever-increasing resistance to currently deployed antimalarials. Here, we explore a series of 4-amino-quinazoline-based sulfonamides, with drug-like physicochemical parameters and a synthetically accessible scaffold. Exemplars exhibit nanomolar potency against blood stage Plasmodium cultures, with up to 300-fold selectivity compared with a mammalian cell line. The compounds are also active against transmissible stages of P. falciparum and are refractory to resistance development. Targeted mass spectrometry reveals that the compounds act as reaction hijacking inhibitors targeting P. falciparum aminoacyl tRNA synthetases (aaRSs). Subtle changes to the chemical structure switch the main target from cytoplasmic tRNA threonine synthetase (PfThrRS) to cytoplasmic asparagine synthetase (PfAsnRS), a change that is associated with increased potency and selectivity. The target preference was confirmed by selective knock-down of different P. falciparum aaRSs and by tolerance selection in a mutator line. Consistent with aaRS targets, exemplar compounds activate the amino acid starvation response. Recombinant enzyme inhibition and thermal stabilisation assays confirm the susceptibility of PfAsnRS to reaction hijacking and show that human AsnRS is less susceptible. A molecular model of Asn-tRNA-bound PfAsnRS reveals that a potent hijacker adopts a pose similar to adenosine 5-monophosphate (AMP). An AlphaFold model of the native PfAsnRS dimer helps explain the tolerance-conferring effect of a mutation at the dimer interface.

The Apolipoprotein E4 (ApoE4) genotype is the most significant genetic risk factor for late-onset Alzheimers disease (AD). A key driver of ApoE4 cellular toxicity is the endo-lysosomal burden resulting from the excessive receptor-mediated uptake of ApoE4 lipoparticles. The high-affinity interaction between lipidated ApoE4 and the Low-Density Lipoprotein Receptor (LDLR) saturates the cellular degradation machinery, correlating with lysosomal alkalinization, lipid accumulation, and cell death. To target this critical interaction interface, which consists of 7 tandem ligand-binding type-A (LA) modules in the human LDLR, we present the design and evaluation of recombinant LDLR minireceptors comprising combinations of these LA modules to competitively antagonize ApoE4 endocytosis. We observe a distinct isoform-dependent uptake dynamic across multiple central nervous system (CNS) cell models, with ApoE4 showing significantly greater total intracellular accumulation than ApoE2. Furthermore, engineered LA peptides selectively bind ApoE4 over human serum LDL and differentially inhibit its uptake, revealing a distinct structural efficacy hierarchy of LA3456 [~] LA345 > LA456 [~] LA45 >> LA34. We establish the resilience of the LA45 minireceptor under physiological serum conditions and identify LA345 as the most stable truncated construct in vitro. Notably, molecular tagging orientation is critical for therapeutic engineering; C-terminal tagging completely preserves the inhibitory function of the minireceptors, whereas N-terminal tagging drastically reduces it. These findings provide a framework for scalable, deliverable inhibition of the ApoE4-LDLR interaction as a potential therapeutic target to mitigate endo-lysosomal accumulation in AD.

In this work we present antibody-metal conjugate as a new subclass of antibody-drug conjugates (ADC) for the chemodynamic therapy of cancer based on the rapid generation of reactive oxygen species (ROS) upon copper reduction. We used conventional therapeutic antibody trastuzumab and DOTA-NHS ester for the design and initial proof-of-concept. Thus, trastuzumab-DOTA-copper conjugate (TDCC) was synthesized. We demonstrate that TDCC retains specific binding to HER2-positive cancer cells with approximately native immunoreactivity and achieves stable copper incorporation with an average drug-to-antibody ratio of up to [~]8. In the presence of physiological reducing agents such as N-acetylcysteine or cysteine, TDCC generates substantial reactive oxygen species (ROS), leading to pronounced cytotoxicity and long-term suppression of clonogenic survival in HER2-positive SK-BR-3 and BT-474 cells. Notably, HER2-negative MDA-MB-231 cells and non-malignant HS5 fibroblasts remain largely unaffected, confirming target-dependent activity. The conjugate remains stable under storage conditions for up to 30 days, and the DOTA linker itself does not interfere with copper-mediated redox chemistry. Our findings identify TDCC as a novel class of targeted oxidative stress inducers that exploit the vulnerability of HER2-positive tumors to copper-mediated cytotoxicity. This strategy not only preserves the specificity of antibody-based delivery but also introduces a distinct mechanism of action capable of bypassing conventional resistance pathways, warranting further preclinical development. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=143 SRC="FIGDIR/small/721915v1_ufig1.gif" ALT="Figure 1"> View larger version (37K): org.highwire.dtl.DTLVardef@7ed6bdorg.highwire.dtl.DTLVardef@1442b2aorg.highwire.dtl.DTLVardef@6dff28org.highwire.dtl.DTLVardef@18aba16_HPS_FORMAT_FIGEXP M_FIG C_FIG

Photoswitchable ligands enable photocontrol of biomolecular activity by binding to targets in an isomer-dependent, light-responsive manner. Recent developments in ionizable photoswitchable ligands greatly expand their applications but introduce a major design challenge: light-responsive binding can depend on isomeric form, chemical substitution, and binding-induced shifts in protonation equilibria. These effects are tightly coupled, subtle in magnitude, and difficult to predict. Consequently, few computational methods have been developed and systematically benchmarked for quantitatively predicting them. Here, we establish a multiscale free-energy method and benchmark it against experimental data for a series of recently developed photoswitchable inhibitors of Escherichia coli dihydrofolate reductase (eDHFR), a crucial target in photopharmacology. Constant pH replica-exchange molecular dynamics and quantum mechanics/molecular mechanics umbrella sampling quantitatively characterize the ligands protonation-state change upon binding to the eDHFR active site. Thermodynamic integration simulations using alternative alchemical pathways, thermodynamic cycles, and protonation-state assignments were evaluated for predicting light-responsive affinity differentials and substituent effects. Direct cis-to-trans transformations with explicit treatment of environment-dependent protonation states best reproduce experimental trends. Compound-to-compound pathways are less reliable because force-field inaccuracies introduce large pK errors that are difficult to correct when protonation/deprotonation processes implicitly enter the thermodynamic cycle. TI simulations that ignore binding-induced protonation-state changes fail to consistently reproduce experimental trends. Protein-ligand and ligand-water interaction analyses further reveal the energetic and structural origins of isomer-dependent binding. This study establishes a systematic free-energy method for designing ionizable photoswitches in photopharmacology.

Class B1 G-protein-coupled receptors (GPCRs), such as the calcitonin gene-related peptide (CGRP) receptor and parathyroid hormone 1 (PTH1) receptor, require native lipid interactions to maintain signalling-competent conformations. However, conventional detergents disrupt these environments. Amphipathic copolymers offer a detergent-free alternative, yet the field still lacks a clear understanding of which polymer architectures best preserve active-state GPCR pharmacology, limiting their broader translational utility. Here, we examine how distinct copolymer chemistries influence the functional integrity of class B1 GPCRs by comparing SMA 2000, DIBMA-12, and the electroneutral sulfo-DIBMA. Using NanoLuciferase bioluminescence resonance energy transfer (NanoBRET) ligand-binding, competition, and mini-G-protein recruitment assays on nanodisc-encapsulated receptors, we show that all three copolymers maintain high-affinity extracellular ligand binding but differ markedly in their ability to preserve intracellular signalling. Despite lower receptor extraction efficiency, only sulfo-DIBMA support mini-Gs engagement at the CGRP receptor and enable G-protein-dependent allosteric modulation at the PTH1 receptor, including conserved ligand affinity and prolonged residence time. These data reveal that polymer charge and backbone chemistry, rather than extraction yield, determine whether native-like nanodiscs retain the conformational landscape required for active-state signalling. Controlling non-specific ligand binding to the copolymer is a key requirement for a successful assay. Our findings identify sulfo-DIBMALP as a particularly superior environment for preserving native signalling behaviour in class B1 GPCRs, highlighting copolymer chemistry as an important determinant in detergent-free membrane protein studies. HIGHLIGHTSO_LISulfo-DIBMA encapsulated nanodiscs preserve active-state conformation of human calcitonin gene-related peptide receptor and parathyroid hormone 1 receptor. C_LIO_LIAll three copolymers (SMA 2000, DIBMA-12 and sulfo-DIBMA) preserve extracellular ligand binding but only sulfo-DIBMA preserves intracellular functional competence, including mini-Gs recruitment and G-protein-dependent allosteric modulation. C_LIO_LICopolymer chemistry, particularly the electroneutral, aliphatic nature of sulfo-DIBMA, may influence the preservation of signalling-competent states in two class B1 GPCRs by minimising charge-driven perturbations during solubilisation. C_LIO_LISulfo-DIBMALP provides a novel platform for studying dynamic membrane proteins with potential to provide mechanistic insights and facilitate drug discovery programmes in the future. C_LI GRAPHICAL ABSTRACT O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=103 SRC="FIGDIR/small/724797v1_ufig1.gif" ALT="Figure 1"> View larger version (20K): org.highwire.dtl.DTLVardef@12db163org.highwire.dtl.DTLVardef@d8efb3org.highwire.dtl.DTLVardef@610dbaorg.highwire.dtl.DTLVardef@1cc3ce4_HPS_FORMAT_FIGEXP M_FIG C_FIG

Quantum effects in biology are unavoidable at the molecular scale; the unresolved question is whether they can remain functionally relevant across the timescale gap between femtosecond molecular dynamics and microsecond-to-millisecond biological function. Here we formalize this mismatch as an equilibrium-to-functionality gap and use tubulin as a stringent open-system test case. We combine secular Lindblad, Redfield, and hierarchical equations of motion (HEOM) treatments to quantify decoherence, non-perturbative relaxation, and the physical amplification required for functional relevance. Equilibrium dephasing yields a conservative [Formula] fs at 310 K, with a generic protein-bath baseline of {approx} 13 fs. A completed 30 ps HEOM trajectory for the full 1JFF tryptophan network shows distributed non-Markovian relaxation, with terminal purity Pur = 0.210 and stretched-exponential exponent {beta}KWW {approx} 0.44, confirming that Redfield is useful as a short-time perturbative comparator but not quantitatively interchangeable with HEOM in this intermediate-coupling regime. We introduce a coherence-utility criterion [U] = [K]{tau}coh/{tau}func, separating required amplification from empirically bounded gain. A thermodynamic uncertainty relation closure shows that neural-scale cascade amplification would require Pmin [~] 10-7 W, about five orders of magnitude above the local microtubule GTP budget. Frohlich pumping is found to be linewidth-gated rather than generically micron-scale; ordered-water cavity QED and geometric subradiance remain experimentally testable but severely constrained candidates. The result is not a model of consciousness, but a reproducible physical benchmark framework for evaluating biological quantum-coherence claims under explicit open-system, energetic, and experimental constraints. Six falsifiable experimental programmes are prioritized, and the full computational framework is released with a validation ledger, cryptographic audit trail, and living supplementary material. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=107 SRC="FIGDIR/small/724047v1_ufig1.gif" ALT="Figure 1"> View larger version (20K): org.highwire.dtl.DTLVardef@19e4f42org.highwire.dtl.DTLVardef@65a719org.highwire.dtl.DTLVardef@1bd63beorg.highwire.dtl.DTLVardef@df77d8_HPS_FORMAT_FIGEXP M_FIG O_FLOATNOGraphical abstract.C_FLOATNO Equilibrium tubulin coherence lies in the femtosecond regime, while functional neural timescales lie in the millisecond regime. Frohlich pumping, QED-cavity protection, and geometric subradiance remain experimentally discriminable non-equilibrium candidates requiring independently bounded amplification. C_FIG FundingThis research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. Versioned computational scope of this releaseThis manuscript reports the theoretical framework, calibrated equilibrium baseline, Redfield/HEOM validation ledger, stratified Bayesian evidence synthesis, classical comparators, and falsifiable experimental design. The release-specific reproduction audit, including the current validation-check total and the SHA-256 fingerprints of the binary production artefacts (.npz, .pkl), is documented in LIVING_SI.md and outputs_data/raw_json/structur al/validation_report.json. A completed 30 ps HEOM production trajectory has been validated on constrained hardware; the master dataset contains the full 8-site population trajectory. A summary of those results is provided in [§]2.2.5. All claims made below are restricted to the numerical and theoretical evidence reported in this manuscript and its associated repository artefacts. The public repository ships the calibrated phenomenological baseline for accessibility; the HEOM production artefacts serve as the non-perturbative validation benchmark. All source figure outputs associated with this release are maintained in the public repository under outputs_data/figures_final/.

Glycosaminoglycans (GAGs) are polyanionic polysaccharides that co-localize with amyloid-{beta} (A{beta}) deposits in Alzheimers disease, yet their mechanistic contribution to A{beta} aggregation remains unclear. Here, we show that GAGs function as pH-responsive electrostatic scaffolds that selectively accelerate A{beta}(1-42) aggregation under mildly acidic, endosomal conditions but not at neutral extracellular pH. Combining experimental and computational approaches, we identify protonated N-terminal histidines as key determinants of GAG binding. Weak interactions between GAGs and the charged Nterminal region of A{beta} promote conformational rearrangements that bring peptides into proximity and expose adjacent hydrophobic aggregation-prone segments, thereby facilitating peptide clustering. Kinetic analyses reveal that aggregation is enhanced in a way consistent with an apparent increase in effective peptide concentration, accelerating nucleation without altering the dominant aggregation pathway. Systematic variation of GAG chain length and sulfation level further demonstrates that aggregation enhancement requires a threshold degree of multivalency, consistent with a clustering-driven mechanism. Together, these findings establish a framework in which pH-dependent electrostatic interactions with GAGs act as molecular triggers of amyloid nucleation, providing insight into how cellular microenvironments regulate the earliest stages of Alzheimers disease pathology.

Orthoflavivirus, such as West Nile Virus (WNV), dengue virus (DENV) and ZIKA virus (ZIKV), are globally distributed pathogens that pose substantial threats to human health. Currently, there are still no effective antiviral drugs for WNV or ZIKV. Despite the availability of two licensed DENV vaccines, their use remains limited due to potential risks, highlighting an urgent need for antiviral drug development. The highly conserved orthoflavivirus protease NS2B/NS3 is required for viral replication, making it a promising anti-flavivirus target. A major challenge, however, is the highly charged active site of this enzyme, which requires charged chemical matters with low bioavailability. An alternative and more attractive strategy is to target potential allosteric sites or folding intermediate states of the protease. In this work, we employ the topology-based coarse-grained G[o] modeling to explore the coupled binding and folding pathways of WNV NS2B/NS3 protease and study the effects of the widely used experimental construct with a G4SG4 linker between NS2B and NS3 on stability and folding. Our results provide a holistic conformational landscape of the protease binding and folding, including several key intermediate states. We find that the presence of the G4SG4 linker alters the folding pathways and destabilizes the NS2B C-terminus. The latter is consistent with experimental observations that the G4SG4 linked protease has lower activity and adopts an open state without the substrate in crystal structures. Together, these findings provide for the first time a complete picture of the binding and folding of the NS2B/NS3 protease and identify important folding intermediate states that could be targeted for allosteric antiviral drug development. TOC Figure O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=157 SRC="FIGDIR/small/722635v1_ufig1.gif" ALT="Figure 1"> View larger version (40K): org.highwire.dtl.DTLVardef@163c356org.highwire.dtl.DTLVardef@ad7b35org.highwire.dtl.DTLVardef@173ed8aorg.highwire.dtl.DTLVardef@1f026bf_HPS_FORMAT_FIGEXP M_FIG C_FIG

The eukaryotic translation initiation factor 4E (eIF4E) is a central regulator of cap-dependent translation and a compelling pharmacological target in disorders marked by protein synthesis dysregulation, including cancer and Fragile X Syndrome (FXS). Among endogenous eIF4E regulators, the CYFIP1-eIF4E interaction is uniquely selective, offering a framework for designing targeted translation modulators. Here, we report Cy-9B, a rationally engineered, stapled peptidomimetic derived from CYFIP1 that binds eIF4E, disrupts eIF4E-eIF4G complex, and suppresses cap-dependent translation. Enhanced-sampling free-energy simulations reveal that Cy-9B engages eIF4E through a non-canonical binding mode. Cy-9B exhibits drug-like properties, including high proteolytic stability and nanomolar affinity. Functionally, Cy-9B inhibits lung cancer cell proliferation, migration, and invasion. In neurodevelopmental disease models, Cy-9B partially normalizes excessive translation in FXS hippocampal neurons and rescues social behavior deficits in a Cyfip1 haploinsufficient Drosophila melanogaster model, restoring wild-type-like performance. Cy-9B emerges as a first-in-class therapeutic candidate for disorders sharing translational dysregulation, highlighting targeted modulation of eIF4E as a broadly applicable and physiologically compatible therapeutic strategy.

Temporal lobe epilepsy (TLE) has an unmet need for precision treatments targeting the seizure focus while avoiding effects on other body parts to minimise side effects. Photopharmacology could enable precision treatment by combining systemic administration of a photoswitchable drug with implantation of an optic fibre in the epileptic focus to induce light-dependent drug conversion from an inactive to an active configuration that interacts with its target receptor to suppress seizures. The photoswitchable {Delta}9-tetrahydrocannabinol ({Delta}9-THC) derivative, azo-THC-3, transitions from an inactive trans to an active cis configuration upon UV irradiation. We demonstrate that local or systemic administration of azo-THC-3 and local UV irradiation in the hippocampus supresses difficult-to-treat seizures in the intrahippocampal kainic acid mouse model of TLE. Furthermore, our findings illustrate that the photoswitch strategy avoids hypolocomotion, a common side effect of systemic {Delta}9-THC administration. As such, we provide the first demonstration of seizure suppression with the systemic administration of a photoswitchable compound and its local photoactivation in the seizure focus. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=133 SRC="FIGDIR/small/720358v1_ufig1.gif" ALT="Figure 1"> View larger version (41K): org.highwire.dtl.DTLVardef@1e42794org.highwire.dtl.DTLVardef@1e26891org.highwire.dtl.DTLVardef@13f2b6forg.highwire.dtl.DTLVardef@3c8e48_HPS_FORMAT_FIGEXP M_FIG C_FIG